| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Listeriosis | 21 | 2025 | 41 | 5.730 |
Why?
|
| Listeria monocytogenes | 27 | 2025 | 59 | 5.440 |
Why?
|
| Phagocytosis | 11 | 2017 | 80 | 1.550 |
Why?
|
| Monocytes | 10 | 2023 | 135 | 1.490 |
Why?
|
| Macrophages | 13 | 2018 | 305 | 1.390 |
Why?
|
| Brain | 9 | 2025 | 769 | 1.360 |
Why?
|
| Interferon-gamma | 6 | 2018 | 108 | 1.110 |
Why?
|
| Neurocysticercosis | 6 | 2024 | 14 | 1.050 |
Why?
|
| MicroRNAs | 2 | 2020 | 302 | 0.950 |
Why?
|
| Endocarditis | 3 | 2021 | 20 | 0.910 |
Why?
|
| Meningitis, Listeria | 1 | 2025 | 1 | 0.910 |
Why?
|
| Bacteria | 5 | 2017 | 286 | 0.890 |
Why?
|
| Mice | 28 | 2025 | 4802 | 0.850 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 98 | 0.820 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2021 | 14 | 0.820 |
Why?
|
| International Classification of Diseases | 2 | 2020 | 38 | 0.790 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2023 | 12 | 0.790 |
Why?
|
| Animals | 36 | 2025 | 10684 | 0.750 |
Why?
|
| Bordetella bronchiseptica | 1 | 2021 | 4 | 0.730 |
Why?
|
| Bordetella Infections | 1 | 2021 | 4 | 0.730 |
Why?
|
| Hospitalization | 2 | 2021 | 201 | 0.730 |
Why?
|
| HIV Infections | 3 | 2021 | 163 | 0.730 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 22 | 0.730 |
Why?
|
| Mice, Inbred C57BL | 17 | 2025 | 1653 | 0.720 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 105 | 0.700 |
Why?
|
| Up-Regulation | 4 | 2018 | 247 | 0.690 |
Why?
|
| Algorithms | 3 | 2021 | 431 | 0.690 |
Why?
|
| Neutrophils | 5 | 2017 | 183 | 0.650 |
Why?
|
| Immunologic Memory | 2 | 2020 | 58 | 0.650 |
Why?
|
| Microglia | 2 | 2018 | 69 | 0.650 |
Why?
|
| Anti-Bacterial Agents | 6 | 2025 | 536 | 0.640 |
Why?
|
| Fluorescent Dyes | 2 | 2017 | 93 | 0.620 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 271 | 0.610 |
Why?
|
| Humans | 46 | 2025 | 28851 | 0.600 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 360 | 0.580 |
Why?
|
| Ampicillin | 4 | 2025 | 14 | 0.570 |
Why?
|
| Bacteremia | 1 | 2018 | 81 | 0.550 |
Why?
|
| Antigens, Ly | 3 | 2008 | 9 | 0.510 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 149 | 0.510 |
Why?
|
| Organophosphonates | 2 | 2014 | 7 | 0.490 |
Why?
|
| Adenine | 2 | 2014 | 17 | 0.490 |
Why?
|
| Encephalitis | 4 | 2018 | 18 | 0.470 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 304 | 0.470 |
Why?
|
| Phagocytes | 4 | 2004 | 15 | 0.460 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 30 | 0.460 |
Why?
|
| Male | 21 | 2024 | 13921 | 0.440 |
Why?
|
| Female | 28 | 2024 | 15624 | 0.430 |
Why?
|
| Bone Diseases | 1 | 2014 | 11 | 0.420 |
Why?
|
| Middle Aged | 15 | 2024 | 7414 | 0.410 |
Why?
|
| Central Nervous System Bacterial Infections | 2 | 2004 | 2 | 0.390 |
Why?
|
| Protein C | 2 | 2012 | 38 | 0.390 |
Why?
|
| Sepsis | 2 | 2012 | 86 | 0.360 |
Why?
|
| Anti-Infective Agents | 2 | 2012 | 78 | 0.360 |
Why?
|
| Endothelium, Vascular | 4 | 2000 | 334 | 0.360 |
Why?
|
| Hemorrhage | 2 | 2012 | 266 | 0.340 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2010 | 2 | 0.330 |
Why?
|
| Food Microbiology | 1 | 2010 | 25 | 0.330 |
Why?
|
| Microscopy, Fluorescence | 4 | 2017 | 163 | 0.330 |
Why?
|
| Water Microbiology | 1 | 2010 | 64 | 0.330 |
Why?
|
| Chorionic Gonadotropin | 1 | 2010 | 22 | 0.320 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 15 | 0.320 |
Why?
|
| Emergencies | 2 | 2020 | 28 | 0.320 |
Why?
|
| Disaster Planning | 2 | 2020 | 24 | 0.320 |
Why?
|
| Disease Outbreaks | 2 | 2020 | 54 | 0.310 |
Why?
|
| Epilepsy | 3 | 2020 | 37 | 0.310 |
Why?
|
| Flow Cytometry | 5 | 2017 | 292 | 0.310 |
Why?
|
| Betacoronavirus | 2 | 2020 | 39 | 0.310 |
Why?
|
| Immunity, Innate | 2 | 2010 | 231 | 0.310 |
Why?
|
| Oligopeptides | 1 | 2010 | 97 | 0.310 |
Why?
|
| Macrophage-1 Antigen | 4 | 2004 | 9 | 0.300 |
Why?
|
| Bacterial Adhesion | 4 | 1998 | 26 | 0.300 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 49 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 53 | 0.300 |
Why?
|
| Cysticercus | 3 | 2023 | 4 | 0.300 |
Why?
|
| Bioterrorism | 3 | 2002 | 28 | 0.290 |
Why?
|
| Cells, Cultured | 9 | 2020 | 1022 | 0.260 |
Why?
|
| Mass Screening | 2 | 2020 | 158 | 0.260 |
Why?
|
| Adult | 13 | 2024 | 8024 | 0.260 |
Why?
|
| Gentamicins | 3 | 2011 | 15 | 0.240 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1507 | 0.220 |
Why?
|
| Taenia solium | 1 | 2024 | 4 | 0.220 |
Why?
|
| Leukocytes | 2 | 2005 | 72 | 0.220 |
Why?
|
| Helminth Proteins | 1 | 2024 | 19 | 0.220 |
Why?
|
| Cell Movement | 3 | 2004 | 376 | 0.220 |
Why?
|
| Young Adult | 6 | 2024 | 2833 | 0.210 |
Why?
|
| Plague | 2 | 2002 | 6 | 0.210 |
Why?
|
| Cytokines | 2 | 2020 | 451 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2021 | 2635 | 0.200 |
Why?
|
| Reference Standards | 2 | 2020 | 57 | 0.200 |
Why?
|
| Epistaxis | 1 | 2023 | 7 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 1998 | 251 | 0.190 |
Why?
|
| RNA, Messenger | 2 | 2018 | 668 | 0.190 |
Why?
|
| Adolescent | 5 | 2024 | 3193 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 56 | 0.190 |
Why?
|
| Biopsy | 1 | 2023 | 208 | 0.180 |
Why?
|
| Levofloxacin | 1 | 2021 | 3 | 0.180 |
Why?
|
| Prevalence | 2 | 2021 | 518 | 0.180 |
Why?
|
| Neurons | 1 | 2004 | 297 | 0.180 |
Why?
|
| Encephalitis, Herpes Simplex | 2 | 2013 | 5 | 0.180 |
Why?
|
| Interleukin-6 | 3 | 2018 | 198 | 0.180 |
Why?
|
| Immunologic Techniques | 1 | 2001 | 12 | 0.180 |
Why?
|
| E-Selectin | 2 | 1998 | 27 | 0.170 |
Why?
|
| Gene Expression | 2 | 2023 | 417 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1998 | 59 | 0.170 |
Why?
|
| Tension-Type Headache | 2 | 2018 | 6 | 0.170 |
Why?
|
| Central Nervous System Infections | 1 | 2000 | 1 | 0.170 |
Why?
|
| Disease Eradication | 1 | 2020 | 9 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2020 | 10 | 0.170 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 416 | 0.170 |
Why?
|
| Epilepsy, Generalized | 1 | 2020 | 2 | 0.170 |
Why?
|
| Viruses | 1 | 2000 | 20 | 0.170 |
Why?
|
| Inpatients | 1 | 2021 | 60 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2004 | 373 | 0.170 |
Why?
|
| Annexin A5 | 1 | 2020 | 24 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 787 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2019 | 268 | 0.160 |
Why?
|
| Receptors, Chemokine | 2 | 2010 | 11 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2020 | 42 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2020 | 102 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 995 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2013 | 874 | 0.160 |
Why?
|
| Medical Records | 1 | 2019 | 51 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 257 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 328 | 0.150 |
Why?
|
| Serum | 2 | 2024 | 11 | 0.150 |
Why?
|
| Registries | 1 | 2021 | 396 | 0.150 |
Why?
|
| Immunophenotyping | 3 | 2010 | 61 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2018 | 67 | 0.150 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 29 | 0.140 |
Why?
|
| Immunization | 1 | 2018 | 121 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 285 | 0.140 |
Why?
|
| Cell Communication | 1 | 2018 | 68 | 0.140 |
Why?
|
| Minocycline | 1 | 2018 | 7 | 0.140 |
Why?
|
| Granuloma | 3 | 2023 | 18 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 29 | 0.140 |
Why?
|
| Escherichia coli | 1 | 2020 | 338 | 0.140 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 38 | 0.140 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 42 | 0.140 |
Why?
|
| Bacterial Proteins | 3 | 1998 | 497 | 0.140 |
Why?
|
| Aged | 4 | 2023 | 5598 | 0.140 |
Why?
|
| Yeasts | 1 | 2017 | 7 | 0.130 |
Why?
|
| Receptors, Complement | 2 | 1996 | 6 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 190 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 1997 | 69 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 125 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 1 | 1998 | 224 | 0.130 |
Why?
|
| Tenofovir | 2 | 2014 | 7 | 0.120 |
Why?
|
| United States Indian Health Service | 1 | 2016 | 18 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 32 | 0.120 |
Why?
|
| Intracellular Space | 1 | 2015 | 12 | 0.120 |
Why?
|
| Colorimetry | 1 | 2015 | 15 | 0.120 |
Why?
|
| Extracellular Space | 1 | 2015 | 26 | 0.110 |
Why?
|
| Microbial Viability | 1 | 2015 | 29 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 114 | 0.110 |
Why?
|
| Oklahoma | 1 | 2018 | 1052 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 465 | 0.110 |
Why?
|
| Microscopy | 1 | 2015 | 38 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 1998 | 273 | 0.110 |
Why?
|
| Central Nervous System | 2 | 2008 | 43 | 0.110 |
Why?
|
| Itraconazole | 1 | 2014 | 9 | 0.110 |
Why?
|
| Histoplasma | 1 | 2014 | 6 | 0.110 |
Why?
|
| Antigens, Fungal | 1 | 2014 | 6 | 0.110 |
Why?
|
| Myxoma | 1 | 2014 | 6 | 0.110 |
Why?
|
| Time Factors | 1 | 2018 | 1613 | 0.110 |
Why?
|
| Histoplasmosis | 1 | 2014 | 10 | 0.110 |
Why?
|
| DNA Primers | 2 | 2010 | 147 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 157 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 14 | 0.110 |
Why?
|
| Amphotericin B | 1 | 2014 | 19 | 0.110 |
Why?
|
| India | 3 | 2020 | 147 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 56 | 0.110 |
Why?
|
| Herpesvirus 1, Human | 2 | 2013 | 24 | 0.100 |
Why?
|
| Ciprofloxacin | 2 | 2011 | 22 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2010 | 272 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 379 | 0.100 |
Why?
|
| United States | 5 | 2021 | 2222 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2020 | 72 | 0.100 |
Why?
|
| Lateral Ventricles | 1 | 2013 | 8 | 0.100 |
Why?
|
| Blood | 2 | 2004 | 34 | 0.100 |
Why?
|
| Interferon Type I | 1 | 2013 | 56 | 0.100 |
Why?
|
| CD11b Antigen | 2 | 2010 | 42 | 0.090 |
Why?
|
| Seizures | 2 | 2023 | 49 | 0.090 |
Why?
|
| Disinfectants | 1 | 2011 | 14 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2024 | 117 | 0.090 |
Why?
|
| Indians, North American | 1 | 2016 | 544 | 0.090 |
Why?
|
| Complement System Proteins | 1 | 1991 | 24 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 44 | 0.090 |
Why?
|
| Actins | 3 | 1998 | 99 | 0.090 |
Why?
|
| Mice, Inbred DBA | 5 | 1996 | 30 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 465 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2010 | 25 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2013 | 1469 | 0.080 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 19 | 0.080 |
Why?
|
| Myelopoiesis | 1 | 2010 | 10 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 81 | 0.080 |
Why?
|
| Inflammation | 4 | 2023 | 667 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 82 | 0.080 |
Why?
|
| Antibody Formation | 1 | 2010 | 77 | 0.080 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 48 | 0.080 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2009 | 1 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 74 | 0.080 |
Why?
|
| Mutation | 2 | 2011 | 867 | 0.080 |
Why?
|
| Immune System | 1 | 2009 | 29 | 0.080 |
Why?
|
| Universities | 2 | 2020 | 124 | 0.080 |
Why?
|
| Blood-Brain Barrier | 2 | 2000 | 97 | 0.080 |
Why?
|
| Antifungal Agents | 2 | 2023 | 69 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2020 | 897 | 0.070 |
Why?
|
| Cytochalasin D | 2 | 1998 | 10 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 285 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 194 | 0.070 |
Why?
|
| Blood Bactericidal Activity | 2 | 2001 | 7 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 8 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2007 | 7 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2022 | 302 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 1032 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 149 | 0.060 |
Why?
|
| Skin | 1 | 2007 | 152 | 0.060 |
Why?
|
| L-Selectin | 1 | 2005 | 11 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 572 | 0.060 |
Why?
|
| Anthrax | 2 | 2002 | 91 | 0.060 |
Why?
|
| Cell Line | 3 | 1995 | 700 | 0.060 |
Why?
|
| Cryptococcosis | 1 | 2005 | 32 | 0.060 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2004 | 3 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 12 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2024 | 79 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 47 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 111 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 17 | 0.050 |
Why?
|
| Biological Transport | 1 | 2004 | 128 | 0.050 |
Why?
|
| Edema | 1 | 2023 | 18 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2023 | 88 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2024 | 196 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 209 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 1996 | 336 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 1056 | 0.050 |
Why?
|
| Antibodies, Helminth | 1 | 2022 | 10 | 0.050 |
Why?
|
| Peritoneal Cavity | 2 | 1992 | 13 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2002 | 56 | 0.050 |
Why?
|
| Proteins | 1 | 2004 | 254 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2001 | 8 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2001 | 32 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 2000 | 8 | 0.040 |
Why?
|
| Phosphatidylserines | 1 | 2020 | 20 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 76 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 65 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2019 | 11 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 174 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 2426 | 0.040 |
Why?
|
| Organ Specificity | 1 | 1999 | 82 | 0.040 |
Why?
|
| Listeria | 2 | 1996 | 15 | 0.040 |
Why?
|
| Genistein | 1 | 1998 | 9 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 1998 | 24 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 23 | 0.040 |
Why?
|
| Swine Diseases | 1 | 2018 | 13 | 0.040 |
Why?
|
| Brain Edema | 1 | 2018 | 21 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1998 | 97 | 0.040 |
Why?
|
| Facial Paralysis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Rhombencephalon | 1 | 1998 | 3 | 0.040 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 1998 | 9 | 0.040 |
Why?
|
| Microcirculation | 1 | 1998 | 113 | 0.040 |
Why?
|
| Hemolysin Factors | 1 | 1998 | 1 | 0.040 |
Why?
|
| Peptide Termination Factors | 1 | 1998 | 2 | 0.030 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1998 | 6 | 0.030 |
Why?
|
| Phospholipase C beta | 1 | 1998 | 4 | 0.030 |
Why?
|
| Type C Phospholipases | 1 | 1998 | 31 | 0.030 |
Why?
|
| Endothelium | 1 | 1998 | 28 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 1998 | 25 | 0.030 |
Why?
|
| Hemolysin Proteins | 1 | 1998 | 53 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1998 | 88 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 94 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 100 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 238 | 0.030 |
Why?
|
| Virulence | 1 | 1998 | 153 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 1996 | 278 | 0.030 |
Why?
|
| Trans-Activators | 1 | 1998 | 118 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1997 | 139 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 524 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 776 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 410 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 422 | 0.030 |
Why?
|
| Hepatitis C Antibodies | 1 | 2016 | 7 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 19 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 1996 | 8 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 612 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2016 | 49 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 68 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 66 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1998 | 634 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2016 | 114 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1994 | 9 | 0.030 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2014 | 1 | 0.030 |
Why?
|
| Base Sequence | 1 | 1995 | 588 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1994 | 60 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 43 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 1998 | 485 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2014 | 92 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1994 | 153 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 270 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 64 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2013 | 5 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2013 | 3 | 0.020 |
Why?
|
| Heart Atria | 1 | 2014 | 177 | 0.020 |
Why?
|
| Thioglycolates | 1 | 1992 | 2 | 0.020 |
Why?
|
| Peptones | 1 | 1992 | 7 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 94 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 31 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2011 | 17 | 0.020 |
Why?
|
| Benzalkonium Compounds | 1 | 2011 | 9 | 0.020 |
Why?
|
| Opsonin Proteins | 1 | 1991 | 5 | 0.020 |
Why?
|
| Cations | 1 | 1991 | 11 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 61 | 0.020 |
Why?
|
| Culture Media | 1 | 2011 | 99 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 697 | 0.020 |
Why?
|
| Kinetics | 1 | 1992 | 553 | 0.020 |
Why?
|
| Endocytosis | 1 | 1991 | 96 | 0.020 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2010 | 10 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2010 | 19 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2010 | 17 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 47 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 15 | 0.020 |
Why?
|
| Neuroglia | 1 | 2009 | 30 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 676 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2009 | 38 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2065 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1350 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 14 | 0.020 |
Why?
|
| Exanthema | 1 | 2007 | 14 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 2126 | 0.020 |
Why?
|
| Solubility | 1 | 2005 | 73 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 2004 | 3 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 202 | 0.010 |
Why?
|
| Biological Warfare | 1 | 2002 | 6 | 0.010 |
Why?
|
| Zoonoses | 1 | 2002 | 13 | 0.010 |
Why?
|
| Q Fever | 1 | 2002 | 2 | 0.010 |
Why?
|
| Brucellosis | 1 | 2002 | 6 | 0.010 |
Why?
|
| Tularemia | 1 | 2002 | 5 | 0.010 |
Why?
|
| Aging | 1 | 2010 | 1016 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 427 | 0.010 |
Why?
|
| Bacillus anthracis | 1 | 2002 | 153 | 0.010 |
Why?
|
| Meningitis, Bacterial | 1 | 1998 | 9 | 0.010 |
Why?
|
| Penicillins | 1 | 1998 | 12 | 0.010 |
Why?
|
| Complement C3b | 1 | 1996 | 4 | 0.010 |
Why?
|
| Streptococcus pyogenes | 1 | 1996 | 30 | 0.010 |
Why?
|
| Species Specificity | 1 | 1996 | 194 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 277 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 314 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1996 | 103 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1996 | 309 | 0.010 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 4 | 0.010 |
Why?
|
| Guanidines | 1 | 1994 | 6 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 1994 | 11 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1994 | 5 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1994 | 8 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1994 | 34 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1994 | 22 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1994 | 20 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 60 | 0.010 |
Why?
|
| Arginine | 1 | 1994 | 42 | 0.010 |
Why?
|
| Necrosis | 1 | 1994 | 85 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1994 | 52 | 0.010 |
Why?
|
| Liver | 1 | 1994 | 471 | 0.010 |
Why?
|